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ABSTR ACT: The association between thyroid function and depression is controversial. Both conditions express many similar symptoms, but the studies 
done give conflicting results. This study draws on a random, population-based sample of 4500 subjects aged 45–75 years old from Finland. The basic clini-
cal study was done in 2007 for 1396 men and 1500 women (64% participation rate). Thyroid stimulating hormone (TSH), free thyroxine (F-T4), and free 
triiodothyronine (F-T3) were measured in 2013 from frozen samples. The 21-item Beck Depression Inventory (BDI-21) was applied to assess depressive 
symptoms (score 10 points). The prevalence of depressive symptoms was 17.5% in women and 12.5% in men. In women, the mean levels of TSH, F-T4, 
and F-T3 without depressive symptoms vs. with the presence of depressive symptoms were 1.92/1.97 mU/L, 13.1/13.1 pmol/L, and 3.91/3.87 pmol/L (NS), 
respectively. In men, the levels were 1.87/1.94 mU/L, 13.5/13.7 pmol/L, and 4.18/4.12 pmol/L (NS), respectively. In multiple regression analysis, TSH had 
no relationship to BDI-21 total score. We found no association between depressive symptoms and thyroid values.
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Introduction
The association between depression and thyroid function, 
especially hypothyroidism, is controversial. The idea of asso-
ciation comes from similarity of symptoms between severely 
depressed and hypothyroid patients, the therapeutic use of 
thyroid hormones in the management of depression, and 
the apparent abnormalities in the hypothalamic–pituitary–
thyroid axis of subjects with depression.1
The many studies in this area give conflicting results. 
The larger studies have shown either no effect or an inverse 
relationship between thyroid function and mood.1 The largest 
study so far is the Norwegian HUNT study.2 The investigators 
found no association between depression, self-reported using 
the Hospital Anxiety and Depression Scale (HADS), and 
thyroid dysfunction in 30,589 individuals aged 40–89 years. 
The same group also analyzed the connections between thy-
roid autoimmunity, depression, and anxiety, finding no asso-
ciations.3 A health database study from Taiwan of 1,000,000 
random subjects found a higher prevalence (1.20% vs. 0.30%) 
and a higher annual incidence (0.40% vs. 0.13%) of hypothy-
roidism in patients with major depressive disorder than in the 
general population. The annual incidence of hyperthyroidism 
was also higher in patients with depression than in the general 
population (0.72% vs. 0.32%, risk ratio 2.06). The correlation 
was especially pronounced in the female subjects.4
Our aim was to study the relationship of thyroid function 
and depressive symptoms, measured with the 21-item Beck 
Depression Inventory (BDI-21),5 in this rather large Finnish 
adult population, because the results of previous studies are 
conflicting in various populations.
Materials and Methods
Study population. The FIN-D2D survey was carried 
out in the hospital districts of Pirkanmaa, the Southern 
Ostrobothnia, and Central Finland between October and 
December 2007.
Journal name: Clinical Medicine Insights: Endocrinology and Diabetes
Journal type: Original Research
Year: 2015
Volume: 8
Running head verso: Saltevo et al
Running head recto: Thyroid function and depressive symptoms
Saltevo et al
30 CliniCal MediCine insights: endoCrinology and diabetes 2015:8
A random sample of 4500 subjects aged 45–74 years, 
which was stratified according to gender, 10-year age groups 
(45–54, 55–64, and 65–74 years), and three geographical areas, 
was selected from the National Population Register in August 
2007. The study participants were invited to a clinical exami-
nation by mail. The overall participation rate was 64%. Thus, 
the main study included 2896 individuals, of which 1396 were 
men (62% of men invited) and 1500 were women (66.7% of 
women invited).
Thyroid values were measured in 2741 subjects (1434 
women and 1307 men). Thyroxin hormone was used by 79 
subjects, and they were excluded from the analysis. The final 
study population was 2662 (1358 women and 1304 men).
The study protocol was approved by the ethics commit-
tee of the Hospital District of Helsinki. All participants gave 
their written, informed consent prior to participation in the 
study. The study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki. The health examination 
was carried out according to the World Health Organization’s 
(WHO’s) MONICA project (Multinational MONItoring of 
trends and determinants in CArdiovascular disease) and the 
WHO’s expert group for glucose assessments.
BDI-21 was applied to assess depressive symptoms.5 
Subjects were categorized as having depression when they 
scored 10 points in the BDI-21. The cut-off point of 10 in 
the BDI-21 has been shown to be a useful measurement for 
detecting depression in various adult populations.6,7
Subjects were asked to rate 21 items from 0 to 3 according 
to how they felt at that time. The items were summed as a total 
score with a range from 0 to 63. The BDI-21 data were missing 
for eight women and five men.
The participants reported their leisure-time physical 
activity (LTPA) according to three categories: (1) low—almost 
completely inactivate, (2) moderate—some physical activity 
more than four hours per week, and (3) high—vigorous 
physical activity many times a week. Current smoking and 
the use of alcohol were also queried. The participants were 
also asked whether they were using thyroid hormones or lipid-
lowering, antihypertensive, antidepressive, or antihyperglyce-
mic medications.
Height, weight, and waist circumference were measured 
by nurses who were specially trained for the survey proce-
dures. Height was measured to the nearest 0.1 cm, and weight 
was measured to the nearest 0.1  kg in light clothing. Body 
mass index (BMI) was calculated as weight (kg) divided by 
the height squared (m2). Blood pressure (BP) was measured 
twice, and the latter was used in the analysis, in a sitting posi-
tion after a minimum of 15 minutes of acclimatization using a 
mercury sphygmomanometer.
Laboratory analysis. After an overnight fast, venous 
blood samples for serum lipid assays were drawn into a 
gel tube containing clot activator and samples for the 
plasma glucose assay into a fluoride citrate tube (Venosafe; 
Terumo Europe). The samples were immediately frozen 
after separating serum and plasma and transferred to the 
laboratory in dry ice once a week for analyses. The rest of 
samples were kept in -70°C.
All basic assays were performed at the Laboratory of 
Analytical Biochemistry at the National Public Health Insti-
tute, Helsinki (Disease Risk Unit, Institute for Health and 
Welfare since 2009), using an ARCHITECT ci8200 analyzer 
(Abbott Laboratories). High-sensitivity C-reactive protein 
(hs-CRP) was measured with an ultrasensitive immunoturbi-
dimetric method using Abbott architect reagents.
Free thyroxine (F-T4), free triiodothyronine (F-T3), and 
thyroid stimulating hormone (TSH) were measured from frozen 
EDTA-plasma samples with Cobas e601 (Roche Diagnostics) 
automated analyzer in the Islab Laboratory of the University of 
Eastern Finland, Kuopio, in the year 2013. The reference val-
ues for free T4, free T3, and TSH were 11–22  pmol/L, 3.1–
6.8  pmol/L, and 0.3–4.2  mU/L, respectively. Serum thyroid 
antiperoxidase antibodies were measured by Architect® (Abbott 
Laboratories) automated analyzer. Analytical sensitivity of the 
assay was 0.16 IU/mL. The upper reference limit was 6.0 IU/mL.
Statistical analysis. The comparisons between the 
groups in demographic, lifestyle, and biochemical charac-
teristics and clinical and drug-treatment data were made by 
t-test, bootstrapped-type t-test, or chi-square test, as appro-
priate. The equality of distributions of the thyroid values was 
tested using the Epps–Singleton two-sample empirical char-
acteristics function test and bootstrap-type analysis of covari-
ance (ANCOVA) taking age, BMI, LTPA, current smoking, 
and alcohol use values as covariates. Linear regression analy-
ses (bootstrap-type standard error) were used to identify the 
appropriate predictors of the BDI-21 total score, using stan-
dardized regression coefficient beta (β). Beta is measured 
in units of standard deviation, and value is a measure of 
how strongly each predictor variable influences the criterion 
(dependent) variable. Cohen’s standard for beta values above 
0.10, 0.30, and 0.50 represents small, moderate, and large 
relationships, respectively.
Results
The mean age of the study population was 59.7 years (women 
59.2 years and men 60.0 years). The mean BMI of both men and 
women was 27.4 kg/m2 (Table 1). Fasting plasma glucose values 
were 6.0 mmol/L in women and 6.5 mmol/L in men. The use 
of antihypertensive, lipid-lowering, and antidepressant medica-
tions was higher in men and women with depression. Hs-CRP 
was not statistically different in men or women with or without 
depression. LTPA was significantly higher both in men and 
women without depression. BP was the same in all groups.
Subclinical hypothyroidism (TSH over reference range 
and normal F-T4) was found in 4.2% of subjects. Subclinical 
hyperthyroidism (TSH under reference rate) was found in 
1.1% of subjects. The prevalence of undiagnosed hypothy-
roidism (TSH over and F-T4 under the reference rate) was 
1.3%. The prevalence of these groups was the same in BDI-21 
Thyroid function and depressive symptoms 
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over and under 10 points compared to subjects with normal 
thyroid values.
Table 2 shows that the prevalence of depressive symp-
toms (BDI-21 10 points) was 17.5% in women and 12.5% in 
men. The mean thyroid values for women without depressive 
symptoms (BDI-21 10 points) vs. with depressive symptoms 
(BDI-21 10 points) were 1.92/1.97 mU/L (NS) for TSH, 
13.1/13.1 pmol/L (NS) for F-T4, and 3.91/3.87 pmol/L (NS) 
for F-T3. For men, the values were 1.87/1.94 mU/L (NS) for 
TSH, 13.5/13.7 pmol/L (NS) for F-T4, and 4.18/4.12 pmol/L 
(NS) for F-T3.
Table 3 shows that in multiple regression analysis, TSH 
has no relationship to BDI-21 total score.
Discussion
This study found no association between depressive symptoms 
and TSH, F-T4, and F-T3 in this Finnish population-based 
cohort. The prevalence of depressive symptoms was 17.5% in 
women and 12.5% in men. This is in line with other studies 
assessing depressive symptoms in Finland.8 The prevalence of 
hypothyroidism or subclinical hypothyroidism in this population, 
measured by s-TSH over the reference range 4.2  mU/L, was 
5.5%. The calculated lifetime risk for developing overt hypothy-
roidism in Denmark was 2.3%, with a threefold excess in women 
(3.5% vs. 1.0% in men).9
We, like many others, excluded the persons (N = 79) who 
used thyroxine from the analysis. This may be an important 
bias because subjects with depressive symptoms and sub-
clinical hypothyroidism are likely to have been on thyroxine 
therapy in countries like Finland where medical care and thy-
roid function tests are easily available. As these subjects are 
excluded, the remaining subjects with clinical hypothyroidism 
are likely to be less symptomatic.1
Several studies have investigated thyroid autoimmunity 
and depression.3 The results are conflicting. Smaller studies, 
one with 583 women with TPO antibody levels 100 mU/L10 
Table 1. the basic demographic, lifestyle and biochemical characteristics of study population according to bdi-21 values 10 and 10.
WOMEN MEN
BDI-21 BDI-21
10 N = 1114 10 N = 236 P-VALUE 10 N = 1136 10 N = 163 P-VALUE
Demographic
age, years, mean (sd) 59 (8) 61 (9) 0.001 60 (8) 62 (9) 0.001
Waist, cm, mean (sd) 90 (13) 94 (14) 0.001 99 (11) 104 (14) 0.001
bMi, mean (sd) 27.2 (5.0) 28.4 (5.4) 0.001 27.3 (4.0) 28.7 (5.0) 0.001
Clinical
Blood pressure, mmHg, mean (SD)
systolic 135 (19) 135 (19) 0.96 138 (18) 138 (18) 0.98
diastolic 80 (9) 80 (9) 0.99 83 (10) 83 (10) 0.64
Biochemical
total cholesterol, mmol/l 5.52 (0.96) 5.60 (0.96) 0.24 5.36 (1.01) 5.10 (0.96) 0.001
hdl cholesterol, mmol/l 1.56 (0.34) 1.51 (0.32) 0.017 1.33 (0.32) 1.26 (0.28) 0.013
total triglycerides, mmol/l 1.24 (0.58) 1.41 (0.72) 0.001 1.49 (1.02) 1.53 (0.84) 0.56
Fasting plasma glucose, mmol/l 5.99 (0.93) 6.18 (1.34) 0.036 6.42 (1.26) 6.50 (1.26) 0.45
hs-CrP, mg/l 2.86 (8.24) 3.21 (5.64) 0.43 2.37 (6.26) 3.51 (11.64) 0.22
Medication
antihypertensive medication, n (%) 354 (32) 98 (42) 0.004 382 (34) 78 (48) 0.001
lipid lowering medication, n (%) 186 (17) 52 (22) 0.051 268 (24) 57 (35) 0.002
Use of antidepressants, n (%) 43 (4) 47 (20) 0.001 22 (2) 28 (17) 0.001
Lifestyle factors
Current smoker, n (%) 208 (19) 59 (25) 0.027 279 (25) 44 (27) 0.50
Current use of alcohol, n (%) 558 (50) 111 (47) 0.39 843 (74) 102 (63) 0.002
LTPA 0.001 0.001
low 164 (15) 73 (33) 191 (17) 58 (38)
Moderate 668 (61) 122 (55) 649 (58) 81 (53)
high 258 (24) 27 (12) 271 (24) 15 (10)
Abbreviations: bdi-21, the 21-item beck depression inventory; bMi, body mass index; ltPa, leisure-time physical activity; hs-CrP, high sensitivity C-reactive 
protein; sd, standard deviation.
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Table 3. Multiple regression analysis for bdi-21 total score.
VARIABLE BETA* P-VALUE
TSH 0.02 (-0.02 to 0.05) 0.39
Male gender -0.09 (-0.13 to -0.05) 0.001
age 0.10 (0.06 to 0.14) 0.001
BMI 0.06 (0.01 to 0.10) 0.008
Current smoker 0.06 (0.02 to 0.10) 0.002
Current use of alcohol -0.05 (-0.09 to -0.01) 0.012
LTPA
low reference 0.001 (p for linearity)
Moderate -0.18 (-0.23 to -0.13)
high -0.24 (-0.29 to -0.13)
hs-CRP 0.03 (-0.01 to 0.06) 0.18
Fasting plasma glucose 0.01 (-0.03 to 0.05) 0.62
lipid lowering medication 0.04 (0.01 to 0.08) 0.030
antihypertensive medication -0.01 (-0.04 to 0.08) 0.90
Note: *standardized beta coefficients.
Table 2. the association between beck depression inventory (bdi-21) scores 10 and 10 and thyroid values (tsh, F-t4, F-t3) in men and 
women.
WOMEN MEN
BDI-21 P-VALUE BDI-21 P-VALUE
10 N = 1114 10 N = 236 CRUDE ADJUSTED* 10 N = 1136 10 N = 163 CRUDE ADJUSTED*
TSH
Mean (sd) 1.92 (1.18) 1.97 (1.38) 0.61 0.63 1.87 (1.24) 1.94 (1.25) 0.54 0.85
Median (iQr) 1.68
(1.12, 2.48)
1.67
(1.01, 2.49)
1.58
 (1.11, 2.25)
1.58
(1.06, 2.53)
F-T4
Mean (sd) 13.1 (2.0) 13.1 (2.1) 0.50 0.10 13.5 (2.0) 13.7 (2.4) 0.25 0.39
Median (iQr) 13.0
(11.9, 14.3)
12.7
(11.7, 14.3)
13.4
(12.2, 14.9)
13.7
(12.2, 15.2)
F-T3
Mean (sd) 3.91 (0.65) 3.87 (0.64) 0.38 0.18 4.18 (0.68) 4.12 (0.68) 0.32 0.13
Median (iQr) 3.88 
(3.48, 4.30)
3.87
(3.46, 4.25)
4.17
(3.70, 4.63)
4.12
(3.66, 4.50)
Notes: *adjusted for age, bMi, current smoking, current alcohol use and ltPa.
Abbreviations: bdi-21, the 21 item beck depression inventory; F-t4, free thyroxine; F-t3, free triiodothyronine; tsh, thyroid-stimulating hormone; sd, standard 
deviation: iQr, interquartile range; ltPa, leisure-time physical activity.
and one with 201 subjects,11 found an association with depres-
sive scores and thyroid autoimmunity. However, the above-
mentioned large Norwegian study found no relation.3
Both the symptoms of depression and biochemical subclin-
ical hypothyroidism (slightly elevated TSH) are common, espe-
cially in the elderly female population. Thus, it is probable that 
they overlap, resulting in thyroxin therapy. Many studies have 
shown poor well-being in subjects on thyroxin, even if it was 
started with adequate biochemical values.12,13 The Danish study 
found that hypothyroidism presented with a broad spectrum of 
symptoms. However, many of these symptoms were also experi-
enced by volunteer control subjects with normal thyroid values.9
Interestingly, a study of a Dutch population-based cohort 
of elderly people (mean age 71 years) found that subjects 
with low-normal TSH levels had more concurrent depressive 
symptoms than those with normal levels as well as a substan-
tially increased risk of developing a depressive syndrome in 
the subsequent years.14
Systemic inflammation increases the risk of depres-
sion, especially in people with type 2 diabetes.15 The effect 
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of low-grade inflammation in people with hypothyroidism is 
not known. In our study, we measured hs-CRP as a marker 
of systemic inflammation, but we did not find any differences 
between groups. On one hand, the depressive people had less 
LTPA than non-depressed people. On the other hand, people 
with depressive symptoms used more antihypertensive, lipid-
lowering, and antidepressant medications.
The strength of this study is a rather large, randomly 
selected population, aged 45–74 years, with both men and 
women. The depressive symptoms were assessed by BDI-21, 
which is widely used and accepted in population-based studies.
The limitations of the study are that TPO-antibodies 
were measured only in 30% of subjects, and we do not have 
data about the subjects’ disease and family history, factors that 
may have important influence on depression. In the beginning, 
the study population was randomly selected from the National 
Population Register database, but only 64% of invited subjects 
enrolled, and we excluded subjects receiving thyroxin-hormone 
therapy. So, the final study population is not randomly selected 
population based.
Conclusion
The association of depressive symptoms and the levels of thyroid 
hormones has been controversial. This study did not find any 
association between TSH, F-T4, and F-T3 values and depres-
sive symptoms.
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